Hypothesis

The primary driver of age‑related decline is not the accumulation of mitochondrial DNA (mtDNA) mutations per se, but the failure of retrograde signaling pathways to adapt to persistent mtDNA‑derived nucleic acid stress. Chronic activation of the cGAS‑STING pathway by leaked mtDNA reprograms nuclear chromatin toward a pro‑inflammatory, senescent state, rendering the nuclear genome a passive effector rather than an independent driver of aging.

Mechanistic Rationale

• mtDNA mutations increase with age, especially G→A transitions from replication errors, and clonal expansions exceed pathogenic thresholds in post‑mitotic tissues G→T mutations indicative of oxidative damage don't increase with age.
• Damaged or excess mtDNA can escape mitochondria and be sensed by the cytosolic DNA sensor cGAS, activating STING and downstream NF‑κB and IRF3 signaling cGAS‑STING, UPRmt may matter as much as the mutations themselves.
• Persistent cGAS‑STING signaling drives a chronic low‑grade inflammation (inflammaging) that alters histone acetylation and methylation patterns, suppressing PGC‑1α and NRF2 while elevating SASP factors.
• This epigenetic shift reduces mitochondrial biogenesis and impairs mitophagy, creating a vicious loop where nuclear gene expression further exacerbates mtDNA stress.
• Nuclear‑targeted interventions (e.g., NAD+ boosters, sirtuin activators) may therefore be ineffective unless the upstream mtDNA‑cGAS‑STING axis is restrained.

Testable Predictions

1. In mtDNA mutator mice, genetic or pharmacological inhibition of cGAS‑STING will attenuate age‑related phenotypes (frailty, cognitive decline, tissue fibrosis) without reducing mtDNA mutation load.
2. Conversely, activating cGAS‑STING in wild‑type mice will prematurely recapitulate aging hallmarks, even when mtDNA remains largely wild‑type.
3. Nuclear chromatin from cGAS‑STING‑inhibited mutator mice will show restored youthful histone marks at promoters of mitochondrial and antioxidant genes, despite unchanged heteroplasmy levels.
4. Pharmacological blockade of STING will extend lifespan in mutator mice to a degree comparable to mitophagy enhancers, but the combination will not be additive, indicating a shared pathway.

Experimental Design

• Model: Use the proof‑reading deficient PolG mtDNA mutator mouse (∼70‑fold increased mtDNA mutation rate) and littermate controls.
• Interventions: a. cGAS knockout (CRISPR) or STING‑specific small‑molecule inhibitor (e.g., C‑176) administered from 3 months of age. b. Control groups receive vehicle or a mitophagy enhancer (e.g., urolithin A) for comparison.
• Readouts:
  • mtDNA heteroplasmy quantification by duplex sequencing (to confirm mutation load remains unchanged).
  • Inflammatory cytokines (IL‑6, TNF‑α) in serum and tissue.
  • Senescence markers (p16^INK4a^, SA‑β‑gal) in kidney, brain, and muscle.
  • Histone acetylation (H3K27ac) and methylation (H3K9me3) ChIP‑seq at PGC‑1α and SOD2 promoters.
  • Functional assays: grip strength, treadmill endurance, Morris water maze.
  • Survival curves.
• Falsifiability: If cGAS‑STING inhibition fails to improve any of the above metrics despite confirmed pathway suppression (phospho‑TBK1/IRF3 levels), the hypothesis is falsified. Conversely, if cGAS‑STING activation in wild‑type mice does not accelerate aging phenotypes, the retrograde signaling premise would be weakened.

Implications

This reframes mitochondrial aging as a signaling problem rather than a pure mutational burden. Therapeutic strategies should prioritize modulating mtDNA‑nucleic acid sensing alongside traditional mito‑protective approaches, potentially unlocking synergistic benefits where nuclear genome interventions finally show efficacy because their upstream trigger has been silenced.